相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The therapeutic potential of second and third generation CB1R antagonists
Resat Cinar et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca2+ signals of mouse pancreatic acinar cells in vitro
Kun-kun Xia et al.
ACTA PHARMACOLOGICA SINICA (2019)
Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system
Fatemeh Khakpai et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands
Gabriele Murineddu et al.
MOLECULES (2019)
Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development
Thuy Nguyen et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
Novel pharmacological actions of trequinsin hydrochloride improve human sperm cell motility and function
Rachel C. McBrinn et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
Maria S. Aymerich et al.
BIOCHEMICAL PHARMACOLOGY (2018)
The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration
Marita Pietrucha-Dutczak et al.
FRONTIERS IN NEUROSCIENCE (2018)
Novel pyrrolocycloalkylpyrazole analogues as CB1 ligands
Battistina Asproni et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2018)
Interaction between NMDA and CB2 function in the dorsal hippocampus on memory consolidation impairment: an isobologram analysis
Mohammad Nasehi et al.
PSYCHOPHARMACOLOGY (2017)
Metabolic side effects induced by olanzapine treatment are neutralized by CBI receptor antagonist compounds co-administration in female rats
P. Lazzari et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)
Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor
Silvia Marino et al.
PHARMACOLOGICAL RESEARCH (2017)
Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity
Marjolein Soethoudt et al.
NATURE COMMUNICATIONS (2017)
The arguments for and against cannabinoids application in glaucomatous retinopathy
Yunes Panahi et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Synthesis, molecular modeling and SAR. study of novel pyrazolo[5,1-f] [1,6]naphthyridines as CB2 receptor antagonists/inverse agonists
Antonio Dore et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Cannabinoids for treatment of glaucoma
Gary D. Novack
CURRENT OPINION IN OPHTHALMOLOGY (2016)
Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties
Valeria Deiana et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2′,4′-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives
Paolo Lazzari et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Cannabinoid CB2 receptors are involved in the regulation of fibrogenesis during skin wound repair in mice
Shan-Shan Li et al.
MOLECULAR MEDICINE REPORTS (2016)
The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism
G. R. Fois et al.
PHARMACOLOGICAL RESEARCH (2016)
Synthesis and Biological Studies of a Novel CB1 Antagonist
K. Banerjee et al.
DRUG RESEARCH (2016)
Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer
Paula Morales et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Tricyclic pyrazoles part 7. Discovery of potent and selective dihydrothienocyclopentapyrazole derived CB2 ligands
Giansalvo Pinna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: A versatile architecture for CB2 selective ligands
Giovanni Pinna et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
An Effective Prodrug Strategy to Selectively Enhance Ocular Exposure of a Cannabinoid Receptor (CB1/2) Agonist
Nello Mainolfi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists
Sangdon Han et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
The Importance of Hydrogen Bonding and Aromatic Stacking to the Affinity and Efficacy of Cannabinoid Receptor CB2 Antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyn-N-[(15,2S,4R)-1, 3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528)
Evangelia Kotsikorou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a Novel Peripherally Restricted Cannabinoid-1 Receptor Antagonist with Significant Weight-Loss Efficacy in Diet-Induced Obese Mice
Chun-Ping Chang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Novel Triaryl Sulfonamide Derivatives as Selective Cannabinoid Receptor 2 Inverse Agonists and Osteoclast Inhibitors: Discovery, Optimization, and Biological Evaluation
Peng Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity
F. J. Meye et al.
MOLECULAR PSYCHIATRY (2013)
NESS06SM reduces body weight with an improved profile relative to SR141716
Andrea Mastinu et al.
PHARMACOLOGICAL RESEARCH (2013)
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile
Andrea Mastinu et al.
BEHAVIOURAL BRAIN RESEARCH (2012)
1-(2 ',4 '-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice
L. Luongo et al.
NEUROBIOLOGY OF DISEASE (2010)
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Roger G. Pertwee
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716):: Design, synthesis, computational analysis, and biological evaluations
Yanan Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
End of the line for cannabinoid receptor 1 as an anti-obesity target?
Dan Jones
NATURE REVIEWS DRUG DISCOVERY (2008)
Endocannabinoids in the retina: From marijuana to neuroprotection
Stephen Yazulla
PROGRESS IN RETINAL AND EYE RESEARCH (2008)
Tricyclic pyrazoles.: 4.: Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2′,4′-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide
Gabriele Murineddu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Chronic topical administration of WIN-55-212-2 maintains a reduction in IOP in a rat glaucoma model without adverse effects
A Hosseini et al.
EXPERIMENTAL EYE RESEARCH (2006)
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: A randomized controlled trial
F Pi-Sunyer et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain
JP Gong et al.
BRAIN RESEARCH (2006)
The endocannabinoid system: Drug targets, lead compounds, and potential therapeutic applications
DM Lambert et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility
LC Zhong et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2005)
Tricyclic pyrazoles.: Part 2:: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzolglindazole-based ligands for cannabinoid receptors
G Murineddu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2005)
Cannabinoids and glaucoma
I Tomida et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2004)
Tricyclic pyrazoles.: part 1:: Synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors
JM Mussinu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2003)
Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract
MA Casu et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Reduction of intraocular pressure and glaucoma progression - Results from the early manifest glaucoma trial
A Heijl et al.
ARCHIVES OF OPHTHALMOLOGY (2002)
Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists
AR Stoit et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2002)
The role of cannabinoids in neurodegenerative diseases
M Glass
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2001)
The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies
A Porcella et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2001)
Expression of CB2 cannabinoid receptor mRNA in adult rat retina
QJ Lu et al.
VISUAL NEUROSCIENCE (2000)
分享论文
